相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart
Imran Ozer et al.
ADVANCED SCIENCE (2022)
Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
Lene H. Garvey et al.
BRITISH JOURNAL OF ANAESTHESIA (2021)
Engineering precision nanoparticles for drug delivery
Michael J. Mitchell et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Maintaining Safety with SARS-CoV-2 Vaccines
Mariana C. Castells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Recent Progress and Opportunities for Nucleic Acid Aptamers
Jonghoe Byun
LIFE-BASEL (2021)
Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies
Bing-Mae Chen et al.
ACS NANO (2021)
The current landscape of nucleic acid therapeutics
Jayesh A. Kulkarni et al.
NATURE NANOTECHNOLOGY (2021)
Noncoding RNA therapeutics - challenges and potential solutions
Melanie Winkle et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Therapeutic strategies for thrombosis: new targets and approaches
Nigel Mackman et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Management of Antithrombotic Agents During Surgery or Other Kinds of Medical Procedures With Bleeding: The MARK Study
Seiji Gotoh et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
RNA therapeutics on the rise
Feng Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
Gergely Tibor Kozma et al.
ADVANCED DRUG DELIVERY REVIEWS (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Paving the Road for RNA Therapeutics
Niels Dammes et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties
Daniel Y. Joh et al.
ADVANCED HEALTHCARE MATERIALS (2019)
Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions
Gergely Tibor Kozma et al.
ACS NANO (2019)
PEGylated liposomes: immunological responses
Marwa Mohamed et al.
SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS (2019)
Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers
Angelo Moreno et al.
CELL CHEMICAL BIOLOGY (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
Yuan-Chin Hsieh et al.
THERANOSTICS (2018)
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity
Yizhi Qi et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Computational design of small transcription activating RNAs for versatile and dynamic gene regulation
James Chappell et al.
NATURE COMMUNICATIONS (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek et al.
GENOME MEDICINE (2017)
Effect of Molecular Architecture on Cell Interactions and Stealth Properties of PEG
Imran Ozer et al.
BIOMACROMOLECULES (2017)
Site-Specific and Stoichiometric Stealth Polymer Conjugates of Therapeutic Peptides and Proteins
Imran Ozer et al.
BIOCONJUGATE CHEMISTRY (2017)
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer
Thomas J. Povsic et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
Nancy J. Ganson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
A. Michael Lincoff et al.
LANCET (2016)
From selection hits to clinical leads: progress in aptamer discovery
Keith E. Maier et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Modulation of the Coagulation Cascade Using Aptamers
Rebecca S. Woodruff et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Creating small transcription activating RNAs
James Chappell et al.
NATURE CHEMICAL BIOLOGY (2015)
Anti-PEG immunity: emergence, characteristics, and unaddressed questions
Qi Yang et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2015)
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Johan J. F. Verhoef et al.
DRUG DISCOVERY TODAY (2014)
Shape matters: size-exclusion HPLC for the study of nucleic acid structural polymorphism
Eric Largy et al.
NUCLEIC ACIDS RESEARCH (2014)
Immunogenicity of Subcutaneously Administered Therapeutic Proteins-a Mechanistic Perspective
Anas M. Fathallah et al.
AAPS JOURNAL (2013)
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial
Thomas J. Povsic et al.
EUROPEAN HEART JOURNAL (2013)
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Wolfgang F. Richter et al.
AAPS JOURNAL (2012)
Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents
Ricardo P. Garay et al.
EXPERT OPINION ON DRUG DELIVERY (2012)
Aptamers and the RNA World, Past and Present
Larry Gold et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
Mauricio G. Cohen et al.
CIRCULATION (2010)
Delivery of Therapeutic Proteins
Dipak S. Pisal et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Aptamers as therapeutics
Anthony D. Keefe et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
Mark Y. Chan et al.
CIRCULATION (2008)
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
M. Y. Chan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K. Dyke et al.
CIRCULATION (2006)
Antidote-mediated control of an anticoagulant aptamer in vivo
CP Rusconi et al.
NATURE BIOTECHNOLOGY (2004)
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
P Caliceti et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Gene silencing in mammals by small interfering RNAs
MT McManus et al.
NATURE REVIEWS GENETICS (2002)
RNA aptamers as reversible antagonists of coagulation factor IXa
CP Rusconi et al.
NATURE (2002)
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism
W Korte et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2000)
分享论文
